Navigation Links
New federal disclosure law may have little impact on drugs prescribed
Date:5/29/2012

AURORA, Colo. (May 29, 2012) A Colorado School of Public Health researcher has found that laws designed to illuminate financial links between doctors and pharmaceutical companies have little or no effect on what drugs physicians prescribe.

"If the policymakers who passed these measures were hoping for a deterrent effect they may be disappointed," said the study's lead author, Genevieve Pham-Kanter, Ph.D., an assistant professor in the Department of Health Systems, Management and Policy at the Colorado School of Public Health and a research fellow at Harvard University and Massachusetts General Hospital.

The report, published Monday in the Archives of Internal Medicine, was prompted by passage of the Physician Payments Sunshine Provision of the Affordable Care Act.

The new federal law requires drug manufacturers to disclose certain payments made to physicians including money for consulting, honoraria, gifts and travel.

"This law is based on the premise that transparency in these transactions is of public importance and that disclosure requirements can act as a deterrent against quid pro quo exchanges physicians may be reluctant to accept large payments from pharmaceutical firms if payments are publicly known and perceived as financial compensation for prescribing certain therapies," said Pham-Kanter who is also an assistant professor of economics at the University of Colorado Denver.

Working with Kavita Nair, Ph.D., associate clinical professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and G. Caleb Alexander, MD, MS, Johns Hopkins Bloomberg School of Public Health, Pham-Kanter examined West Virginia and Maine, two states with disclosure laws already on the books.

She specifically investigated the effect of the laws on the prescribing of HMG-CoA reductase inhibitors (statins) and selective serotonin reuptake inhibitors (SSRIs). Marketing plays a heavy role in a physician's choice of therapy since members of each class of drug are similar and highly substitutable, Pham-Kanter said.

The researchers theorized that if disclosure laws were effective and doctors were deterred from taking payments from pharmaceutical companies, they in turn would be less likely to prescribe branded statins and SSRIs over similar generic drugs.

Using a wide variety of public data, they compared Maine, which enacted a disclosure law in 2004, with New Hampshire and Rhode Island, two demographically similar states without such laws. Then they compared West Virginia, which also passed its disclosure law in 2004, with Kentucky and Delaware which had none.

In Maine, the law was associated with a 0.8 percentage point reduction in the use of branded statins compared to New Hampshire, and a 5.3 percentage point reduction compared to Rhode Island. The researchers found little to no effect in West Virginia.

"Our results show that the disclosure laws in the two states we examined had a negligible to small effect on physicians switching from branded therapies to generics and no effect on reducing prescription costs," said Pham-Kanter.

She noted that despite the laws, accessing information about how much money a physician received from a pharmaceutical company is still difficult and opaque. Much of the information is not on-line yet.

"Transparency is important in its own right, but if deterring unnecessary, costly prescribing is a concern for policymakers, more direct action may be required," Pham-Kanter said.


'/>"/>

Contact: David Kelly
david.kelly@ucdenver.edu
303-315-6374
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Federal grant enables HIV testing, treatment in the Augusta area
2. Study finds federal amendments increased gun sales diverted to criminals
3. UofL geriatrician selected for new federal Innovation Advisors Program
4. Cleveland Clinic nephrologist earns Federal grant for study of kidney disease management
5. Requests for Alzheimers disease research grants up by 33 percent, as federal funding in doubt
6. Federal government releases environmental, health, and safety research strategy for nanotechnology
7. Hasbro Childrens Hospital now part of nations first federally- funded pediatric research network
8. Radiologists urged to study federal regulations relating to meaningful use
9. Federal investment in electronic health records likely to reap returns in quality of care
10. Pro athletes ought to bargain outside federal court, legal scholar says
11. CMAJ calls on federal government to protect Canadians from unsafe drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of lingering ... for over ten long years has been waiting to release this powerful insight about forgiveness ... been serving the Lord for over twenty years, and he has been preaching and teaching ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers ... creation of published author, Gene Gaapf, a retired truck driver, and a long-time writer, ... writing since high school and have many different titles,” Gaapf mentions about his different ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... 19, 2017 The global immunomodulators market ... 2025, according to a new study by Grand ... be predominantly driven by high R&D investments employed ... production of new and therapeutically advanced drugs. This ... at an unprecedented rate into the immunomodulators market ...
(Date:1/19/2017)... Jan. 19, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
Breaking Medicine Technology: